Literature DB >> 12370820

Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes.

Masahiro Aoki1, Vera Sobek, Daniel J Maslyar, Andreas Hecht, Peter K Vogt.   

Abstract

Genetic analysis of beta-catenin-induced oncogenic transformation in chicken embryo fibroblasts (CEF) revealed the following prerequisites for oncogenicity: (1) removal of the N terminal phosphorylation sites targeted by glycogen synthase kinase 3beta (GSK3beta), (2) retention of the N terminal transactivation domain, and (3) retention of the armadillo repeats. The C terminal transactivation domain played an ancillary role in the transformation of CEF. There was a rough correlation between the transforming activity of various beta-catenin constructs and their transactivation of the TOPFLASH reporter. Expression levels of the candidate target genes of beta-catenin-LEF, cyclin D1 and myc were not correlated with each other or with the transforming activity of beta-catenin constructs. A new target gene, coding for inositol hexakisphosphate kinase 2 (IP6K2) was identified. Its expression showed concordance with the transforming activity of beta-catenin constructs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370820     DOI: 10.1038/sj.onc.1205796

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation.

Authors:  James S Stover; Jin Shi; Wei Jin; Peter K Vogt; Dale L Boger
Journal:  J Am Chem Soc       Date:  2009-03-11       Impact factor: 15.419

2.  Wnt activation and alternative promoter repression of LEF1 in colon cancer.

Authors:  Tony W-H Li; Ju-Hui T Ting; Noriko N Yokoyama; Alla Bernstein; Marc van de Wetering; Marian L Waterman
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  The GM-CSF receptor utilizes β-catenin and Tcf4 to specify macrophage lineage differentiation.

Authors:  Anna L Brown; Diana G Salerno; Teresa Sadras; Grant A Engler; Chung H Kok; Christopher R Wilkinson; Saumya E Samaraweera; Timothy J Sadlon; Michelle Perugini; Ian D Lewis; Thomas J Gonda; Richard J D'Andrea
Journal:  Differentiation       Date:  2011-10-08       Impact factor: 3.880

4.  Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1.

Authors:  Feng Rao; Jing Xu; Chenglai Fu; Jiyoung Y Cha; Moataz M Gadalla; Risheng Xu; James C Barrow; Solomon H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-23       Impact factor: 11.205

5.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein.

Authors:  Jin Shi; Peter K Vogt
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

7.  Beta-catenin regulation during the cell cycle: implications in G2/M and apoptosis.

Authors:  David Olmeda; Susanna Castel; Senén Vilaró; Amparo Cano
Journal:  Mol Biol Cell       Date:  2003-04-04       Impact factor: 4.138

Review 8.  Inositol pyrophosphates: structure, enzymology and function.

Authors:  Christopher John Barker; Christopher Illies; Gian Carlo Gaboardi; Per-Olof Berggren
Journal:  Cell Mol Life Sci       Date:  2009-08-28       Impact factor: 9.261

9.  Direct interaction of tumor suppressor CEACAM1 with beta catenin: identification of key residues in the long cytoplasmic domain.

Authors:  Lan Jin; Yun Li; Charng-Jui Chen; Mark A Sherman; Keith Le; John E Shively
Journal:  Exp Biol Med (Maywood)       Date:  2008-04-29

10.  Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells.

Authors:  Clotilde Billottet; Nadia Elkhatib; Jean-Paul Thiery; Jacqueline Jouanneau
Journal:  Mol Biol Cell       Date:  2004-07-28       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.